Skip to main content
lexblog.com/lib/TPVQJN66viewrecordjson
LEX-WK-TPVQJN66crawled 2022-08-25 14:22Z

CMA Fines GlaxoSmithKline and Several Generic Companies £45 million for Delaying Market Entry of Generic Paroxetine in the UK

Inside EU Life Sciences · Inside EU Life Sciences · Published February 12, 2016

Work details

firm or organization
Covington & Burling LLP
published
2016-02-12

Citation

Inside EU Life Sciences, CMA Fines GlaxoSmithKline and Several Generic Companies £45 million for Delaying Market Entry of Generic Paroxetine in the UK, Inside EU Life Sciences (February 12, 2016) [The Library at LexBlog, LEX-WK-TPVQJN66, lexpid.org/TPVQJN66]